Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions
- 30 April 2009
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 36 (2), 112-125
- https://doi.org/10.1053/j.seminoncol.2008.12.003
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)Gynecologic Oncology, 2008
- Relevant molecular markers and targetsGynecologic Oncology, 2006
- Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trialAnnals of Oncology, 2006
- Novel therapeutic agents in ovarian cancerEuropean Journal of Surgical Oncology, 2006
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Hexamethylmelamine as a Single Second-Line Agent in Ovarian Cancer: Follow-up Report and Review of the LiteratureGynecologic Oncology, 1997
- Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinumEuropean Journal of Cancer, 1997
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trialsEuropean Journal Of Cancer, 1995
- Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancerZeitschrift für Krebsforschung und Klinische Onkologie, 1992